F. NostenF. O. ter KuileC. LuxemburgerC. WoodrowT. ChongsuphajaisiddhiN. J. WhiteD. E. KyleShoklo Malaria Research UnitMahidol UniversityAcademic Medical Centre, University of AmsterdamArmed Forces Research Institute of Medical Sciences, ThailandJohn Radcliffe Hospital2018-08-102018-08-101993-04-24The Lancet. Vol.341, No.8852 (1993), 1054-1056014067362-s2.0-0027404778https://repository.li.mahidol.ac.th/handle/20.500.14594/22728In a prospective electrocardiographic study of Karen patients with acute uncomplicated falciparum malaria, mefloquine (25 mg/kg) had no cardiac effects (n=53), but halofantrine (72 mg/kg) induced consistent dose-related lengthening of the PR and QT intervals in all 61 patients treated. The likelihood of significant QTc prolongation (by more than 25% or a QTc of 0·55 s1/2or more) was greater after halofantrine as retreatment following mefloquine failure than as primary treatment (7/10 vs 18/51; relative risk 2·0 [95% Cl 1·1-3·4], p = 0·04). More than 60% of the effect occurred with three doses of halofantrine (24 mg/kg). The arrhythmogenic potential of halofantrine should now be investigated. © 1993.Mahidol UniversityMedicineArticleSCOPUS10.1016/0140-6736(93)92412-M